Chief Financial Officer · Lexeo Therapeutics, Inc. (LXEO)

Louis Tamayo

Louis Tamayo, Chief Financial Officer of Lexeo Therapeutics, Inc., received total compensation of $1665915 for fiscal year 2025. His disclosed base salary was $181818, cash bonus was $197760, and stock-based compensation was $1281563.

FY2025 is the first fiscal year CompBrief holds for Louis Tamayo as a named executive officer of Lexeo Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,665,915

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Louis Tamayo compensation by year

Lexeo Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Lexeo Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$181,818
Bonus$0
Stock awards$215,550
Option awards$1,066,013
Non-equity incentive$197,760
Pension and deferred compensation$0
All other$4,774
Total$1,665,915

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lexeo Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-193930, and prior-year filings. Open the filing on EDGAR.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU45,000$446,850—
Option280,000—$4.79

Per the Outstanding Equity Awards at Fiscal Year-End table in Lexeo Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Lexeo Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
R. Nolan TownsendChief Executive Officer and Director$3,650,940
Jenny RobertsonFormer Chief Legal Officer$2,145,883
Louis Tamayo · this pageChief Financial Officer$1,665,915

The full Lexeo Therapeutics compensation record

free company brief

This page is one person within Lexeo Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Lexeo Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lexeo Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy